Taken together, these studies suggest that different mechanisms contribute to inactivate SMAD4 and possibly the tumor suppressive arm of the TGFβ pathway, both in eCCA, involving SMAD4 inactivating point mutations, and in iCCA, involving a transcriptional down-regulation of SMAD4. The gene discussed is SMAD4; the disease is neoplasm.